Levofloxacin: Difference between revisions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) parser-claude batch MedTemplate pre-fill, Top 300 #231 |
MDElliottMD (talk | contribs) home-claude category backfill (parser-claude gap closure) |
||
| Line 21: | Line 21: | ||
== References == | == References == | ||
<references /> | <references /> | ||
[[Category:Fluoroquinolones]] | |||
[[Category:Antibacterials]] | |||
Latest revision as of 10:43, 23 May 2026
Levofloxacin
Levaquin (US brand discontinued); generic and ophthalmic Quixin/Iquix
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Community-acquired pneumonia0, Acute bacterial sinusitis0, Complicated UTI / pyelonephritis0, Bacterial prostatitis0, Anthrax prophylaxis and treatment0, Bacterial conjunctivitis/keratitis (topical)0
Pharmacy
Starting dose
500-750 mg PO/IV once daily
Preparations
250, 500, 750 mg tablets; 25 mg/mL oral solution; 25 mg/mL IV (premix bags 250, 500, 750 mg); 0.5%, 1.5% ophthalmic solutions
US FDA Max
750 mg/d
Pharmacology
Routes
Oral, IV, topical ophthalmic
Onset
Hours
Duration
24 hours
Half-life
~6-8 hours[1]
Bioavailability
~99% (oral; matched 1:1 IV-to-PO conversion)[1]
Pregnancy
Avoid in pregnancy where alternatives exist (animal cartilage toxicity; class-wide concern).[citation needed]
Legal status
Purported mechanism
Levofloxacin (the L-enantiomer of ofloxacin) inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, blocking supercoiling and decatenation required for DNA replication; the result is bactericidal.0 Among "respiratory fluoroquinolones" (with moxifloxacin and gemifloxacin) — broader S. pneumoniae and atypical coverage than ciprofloxacin, making it more useful in CAP. QT prolongation, hypoglycemia, and aortic dissection signals are recognized class effects[1].
References
- ↑ 1.0 1.1 1.2 1.3 FDA Prescribing Information, Levaquin (levofloxacin), Janssen, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s072,020635s075,021721s041lbl.pdf